We are live on ! Find out more
ACM

Atika Capital Management Portfolio holdings

AUM $796M
1-Year Est. Return 167.57%
This Fund
S&P 500
This Quarter Est. Return
-4%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$711M
AUM Growth
-$230M
Cap. Flow
-$231M
Cap. Flow %
-32.53%
Top 10 Hldgs %
46.66%
Holding
104
New
20
Increased
21
Reduced
18
Closed
42

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$28.9M
2
VRT icon
Vertiv
VRT
+$14.3M
3
SPOT icon
Spotify
SPOT
+$11.3M
4
NFLX icon
Netflix
NFLX
+$8.89M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$7.8M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$10.9M
2
GLNG icon
Golar LNG
GLNG
+$8.4M
3
REAL icon
The RealReal
REAL
+$8.15M
4
TSM icon
TSMC
TSM
+$7.66M
5
BSX icon
Boston Scientific
BSX
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 27.28%
2 Technology 16.26%
3 Consumer Discretionary 13.3%
4 Industrials 11.04%
5 Communication Services 10.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WRBY icon
101
Warby Parker
WRBY
$3.27B
-103,338
Closed -$2.5M
ALAB icon
102
Astera Labs
ALAB
$58B
-24,300
Closed -$3.22M
BECN
103
DELISTED
Beacon Roofing Supply, Inc.
BECN
-62,400
Closed -$6.34M
ITCI
104
DELISTED
Intra-Cellular Therapies Inc.
ITCI
-73,000
Closed -$6.1M

Similar funds

Atika Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Atika Capital Management held 104 positions worth $711M, down 24% from $941M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Atika Capital Management withdrew a net $231M in Q1 2025, closing 42 positions and reducing 18 holdings. Its most notable exit was United Therapeutics, an estimated $10.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 25% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Atika Capital Management opened a new position in Teva Pharmaceuticals worth $6.72M.

  • Atika Capital Management's largest Q1 2025 buy was Teva Pharmaceuticals: 436,900 shares worth $6.72M.
  • Atika Capital Management added most to Amazon in Q1 2025, an estimated $28.9M increase.
  • Atika Capital Management's biggest Q1 2025 reduction was The Gap Inc, cutting an estimated $6.06M.
  • Atika Capital Management fully exited United Therapeutics in Q1 2025, selling an estimated $10.9M.
  • Atika Capital Management's ten largest holdings make up 47% of its $711M portfolio in Q1 2025.
  • Atika Capital Management opened 20 new positions and closed 42 in Q1 2025.
  • Atika Capital Management's portfolio value fell 24% quarter-over-quarter to $711M.

Based on Atika Capital Management's 13F filing for Q1 2025, filed 14 May 2025.